CD8A and neoplasm: Ultimately, it greatly facilitated antigen presentation to the DC and its subsequent homing to the dLN and triggered a broad-spectrum anti-tumor CD8 T-cell response, which resulted in significant inhibition of B16 tumor growth, but not all tumors were completely eradicated in each treatment group, suggesting that further optimization of vaccine dosage is required to enhance the immune response of cytotoxic CD8 T-cells in future work and that the assembly of each epitope was also adjusted ratios to tailor personalized peptide vaccines.